ASGCT Virtual: We are thoroughly enjoying the “live” annual meeting of the American Society of Gene and Cell Therapy (ASGCT).
Unlike other virtual meetings that have recorded presentations, ASGCT are running a live format, with presenters giving their talks in real-time from wherever in the world they may be. By and large this has worked well, and it definitely felt as though you were at the meeting.
We are also enjoying the ePoster hall, and in particular, the short audio tour that many presenters have made to take you through their poster. Obviously, it’s not a substitute for in-person contact, but who would want to be in a crowded poster hall or meeting room in these uncertain times with the potential for the coronavirus lurking about?
Earlier today we “attended” a virtual ASGCT20 scientific session with oral presentations organized by the American Society for Transplantation and Cellular Therapy (ASTCT) on Engineering Immunity.
Four speakers focused on CAR T cell therapy in non-B cell malignancies – what did we learn? It turns out the answer was quite a bit!
To find out more about our oncology analysis and get a heads up on insights and commentary emerging from the ASGCT meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
What stood out at TCT in Orlando?
Orlando – There have been numerous useful insights into the future of next generation of CAR T cell therapies at the Transplantation and Cellular Therapy Meeting (TCT) that’s currently underway here in Florida.
TCT (formerly BMT Tandem) is the combined meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).
It should come as no surprise that the transplant community have embraced cellular therapies.
As we start what experts such as Carl June refer to as “the decade of cell therapy,” what does the next generation of CAR T cell therapy likely look like and how will we overcome some of the challenges associated with this approach?
In this post we’re following developments in the field, and sharing what we’ve learnt so far from thought leaders at the TCT meeting. This is the latest in our recent mini-series of posts on future developments in cellular therapy.
To gain insights from our oncology coverage and get a heads up on our latest analysis and commentary subscribers can log-in or you can click to gain access to BSB Premium Content.
How Will Adoptive Cell Therapy Crack Solid Tumours? – This was the provocative question raised by the title of Dr Malcolm Brenner’s keynote lecture at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium held last week in San Francisco, ”Adoptive T cell Therapy: Target Solid Tumors by CARs or TCRs?”
Malcolm K Brenner, MD PhD is the Director of the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas.
ASCO have just named CAR-T cell immunotherapy as its “2018 Cancer Advance of the Year” so it’s timely to take a look at where we are in the adoptive cell therapy field and where it may be going?
We’ve been writing about adoptive cell therapies (ACT) such as CAR T cell therapy since 2011. Indeed, I vividly recall one of my early interviews about it at ASH 2013 (See post: Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens)”.
In recent years, CAR T cell therapy has made tremendous progress in hematologic malignancies, gaining FDA approval last year in relapsed/refratory paediatric ALL and non-Hodgkin lymphoma (NHL). We have not seen the same efficacy in solid tumours as yet, and this remains one of the key challenges in the field today.
In this post, we take a look at the perspectives Dr Brenner offered in his keynote lecture at ASCO-SITC and the potential impact they may have on the landscape.
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.